Research Analysts’ Recent Ratings Changes for Amphastar Pharmaceuticals (AMPH)

Several analysts have recently updated their ratings and price targets for Amphastar Pharmaceuticals (NASDAQ: AMPH):

• 11/9/2026 – Amphastar Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 11/6/2026 – Amphastar Pharmaceuticals had its price target raised by Wells Fargo & Company from $20.00 to $25.00. They now have an “equal weight” rating on the stock.
• 11/4/2026 – Amphastar Pharmaceuticals was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 11/1/2026 – Amphastar Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/24/2026 – Amphastar Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/16/2026 – Amphastar Pharmaceuticals was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 10/3/2026 – Amphastar Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 10/2/2026 – Amphastar Pharmaceuticals had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 9/12/2026 – Amphastar Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Amphastar Pharmaceuticals Trading Down 1.1%

Shares of Amphastar Pharmaceuticals stock opened at $29.06 on Wednesday. The company has a quick ratio of 2.36, a current ratio of 3.32 and a debt-to-equity ratio of 0.75. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of 13.27, a price-to-earnings-growth ratio of 5.73 and a beta of 0.93. The business has a fifty day simple moving average of $25.63 and a 200-day simple moving average of $22.36. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $31.00.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, November 5th. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.28. Amphastar Pharmaceuticals had a return on equity of 15.31% and a net margin of 13.27%. The firm had revenue of $207.61 million for the quarter, compared to analyst estimates of $197.52 million. On average, equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.43 EPS for the current fiscal year.

Insider Transactions at Amphastar Pharmaceuticals

In other news, CFO William Peters sold 12,631 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $28.99, for a total transaction of $366,172.69. Following the completion of the transaction, the chief financial officer owned 167,076 shares in the company, valued at approximately $4,843,533.24. This trade represents a 7.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total transaction of $239,400.00. Following the completion of the transaction, the executive vice president directly owned 169,203 shares in the company, valued at $4,050,719.82. This represents a 5.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock valued at $1,232,836 over the last three months. 29.60% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets generic and proprietary medicines, with a focus on products that can be technically challenging to produce. Its offerings include injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients. The company’s products include treatments and emergency medicines such as enoxaparin, glucagon and epinephrine products. Amphastar also markets BAQSIMI, a nasal powder used to treat severe low blood sugar, and Primatene MIST, an over-the-counter asthma inhaler.